Meridian Bioscience Comments on FDA Press Statement Regarding Its Warning Letter Issued to Magellan Diagnostics
CINCINNATI, Oct. 23, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that the FDA has issued a Warning Letter related to matters at its Magellan Diagnostics subsidiary. In our July 27, 2017 press release, Meridian indicated that it expected Magellan would receive a Warning Letter based on the observations from the FDA’s inspection, […]